Company Filing History:
Years Active: 2020
Title: Innovations in Monoclonal Antibodies: The Work of Chiung-Chi Kuo
Introduction
Chiung-Chi Kuo, a prominent inventor based in Stanford, CA, has made significant contributions to the field of biomedicine through his innovative work on monoclonal antibodies. His research primarily focuses on the development of humanized and chimeric antibodies aimed at targeting CD81, a critical protein involved in various biological processes.
Latest Patents
Chiung-Chi Kuo holds a patent for "Humanized and chimeric monoclonal antibodies to CD81." This patent encompasses the creation of humanized or chimeric anti-CD81 monoclonal antibodies that bind effectively to human CD81. These antibodies are notable for their therapeutic applications, particularly in the reduction or prevention of tumor metastasis. Additionally, the patent provides essential sequences for heavy chain and light chain variable regions, along with the associated complementarity-determining region (CDR) sequences, which are vital for the antibody's functionality.
Career Highlights
Kuo is affiliated with the Leland Stanford Junior University, where he engages in cutting-edge research on therapeutic antibodies. His work represents a significant advancement in cancer treatment methodologies, contributing to the broader understanding of how to combat tumor progression through innovative biological solutions.
Collaborations
Throughout his career, Chiung-Chi Kuo has collaborated with esteemed colleagues such as Shoshana Levy and Aurelien Marabelle. These partnerships reflect the collaborative spirit of scientific research and emphasize the importance of teamwork in driving innovation in therapeutic development.
Conclusion
The contributions of Chiung-Chi Kuo to the field of monoclonal antibodies signify a notable advancement in medical science. His patent for humanized and chimeric anti-CD81 antibodies serves as a foundation for potential new therapies aimed at preventing cancer metastasis, marking him as a key figure in the realm of biomedical innovation. As research continues to evolve, Kuo's work is likely to inspire further advancements in the treatment of cancer and other diseases.